慢性疼痛治療​​的全球市場：市場規模和佔有率分析 - 趨勢、驅動因素、競爭格局、未來預測（2024-2030）

市場概況

全球慢性疼痛治療​​市場預計2023年營收將達976億美元，2030年將達1596億美元，2024年至2030年複合年增長率為7.4%。 該產業發展的關鍵原因包括政府對這些解決方案的支持力度增加、老年人口不斷增加以及慢性病發病率上升。

關鍵見解

由於嚴重頭痛、背痛和臉部疼痛等慢性疼痛疾病的增加，藥品類別預計將以約 7.7% 的複合年增長率增長，並引領行業佔有率。

2023年，由於纖維肌痛、骨關節炎和類風濕關節炎等肌肉骨骼疾病的高發，肌肉骨骼類別的佔有率為40%。

從2019年到2021年，美國有5,320萬成年人將患有上述疾病：不同類型的關節炎（包括類風濕性關節炎）、痛風、紅斑性狼瘡或纖維肌痛症。

由於關節炎盛行率不斷上升以及腰痛成為全球殘疾的主要原因等因素，預計到預測期結束時，肌肉骨骼領域的複合年增長率將達到 7.3%。

根據跡象，癌症疼痛類別預計在預測期內將以 8.0% 的複合年增長率增長。

依地區劃分，在醫療基礎設施進步、可支配收入增加、老年人口增長和慢性疼痛患病率的推動下，亞太地區在預測期內將以 7.8% 的複合年增長率增長最快。

到 2023 年，北美地區將佔該行業佔有率的 55%，該地區因其發達的醫療基礎設施、高昂的醫療成本以及廣泛的先進疼痛治療解決方案而受到青睞。

本報告分析了全球慢性疼痛治療​​市場，包括市場的基本結構和最新情況、主要促進和抑制因素以及全球、依地區和主要國家的市場規模前景（以貨幣形式計算） ，2017-2030） ，依細分市場劃分的詳細趨勢、當前市場競爭狀況以及主要公司概況。

目錄

第一章研究範圍

第二章研究方法

第 3 章執行摘要

第 4 章市場指標

第五章產業展望

• 市場動態
  • 趨勢
  • 促進因素
  • 抑制因素/課題
  • 促進/抑制因子影響分析
• 新型冠狀病毒感染 (COVID-19) 的影響
• 波特五力分析

第六章世界市場

• 摘要
• 市場收入：依產品分類（2017-2030 年）
• 市場收入：依指標分類（2017-2030 年）
• 市場收入：依應用分類（2017-2030 年）
• 市場收入：依分銷管道劃分（2017-2030 年）
• 市場收入：以最終用戶劃分（2017-2030 年）
• 市場收入：依地區劃分（2017-2030 年）

第七章北美市場

• 摘要
• 市場收入：依產品分類（2017-2030 年）
• 市場收入：依指標分類（2017-2030 年）
• 市場收入：依應用分類（2017-2030 年）
• 市場收入：依分銷管道劃分（2017-2030 年）
• 市場收入：以最終用戶劃分（2017-2030 年）
• 市場收入：依國家/地區劃分（2017-2030 年）

第8章歐洲市場

第9章亞太市場

第10章拉丁美洲市場

第十一章中東及非洲市場

第12章美國市場

• 摘要
• 市場收入：依產品分類（2017-2030 年）
• 市場收入：依指標分類（2017-2030 年）
• 市場收入：依應用分類（2017-2030 年）
• 市場收入：依分銷管道劃分（2017-2030 年）
• 市場收入：以最終用戶劃分（2017-2030 年）

第十三章加拿大市場

第14章德國市場

第十五章法國市場

第十六章英國市場

第十七章義大利市場

第十八章西班牙市場

第十九章日本市場

第20章中國市場

第21章印度市場

第22章澳洲市場

第23章韓國市場

第24章巴西市場

第25章墨西哥市場

第26章沙烏地阿拉伯市場

第27章南非市場

第 28 章阿聯酋 (UAE) 市場

第29章競爭態勢

• 市場參與者及其提供的產品/服務的列表
• 主要公司的競爭基準
• 各大公司的產品基準
• 近期策略發展狀況

第30章公司簡介

• Eli Lilly and Company
• GlaxoSmithKline plc
• Pfizer Inc.
• Medtronic plc
• Abbott Laboratories
• Boston Scientific Corporation
• Novartis AG
• Johnson & Johnson Services Inc.
• AstraZeneca PLC
• Bristol-Myers Squibb Company
• Becton, Dickinson and Company
• Sanofi S.A.
• Teva Pharmaceutical Industries Limited
• AbbVie Inc.
• Paradigm Biopharmaceuticals Limited

第31章附錄

Market Overview

The chronic pain treatment market achieved a revenue of USD 97.6 billion in 2023 and is projected to experience a compound annual growth rate (CAGR) of 7.4% from 2024 to 2030, reaching USD 159.6 billion by 2030. The major reasons accountable for the development of the industry include the growing government backing for these solutions, increasing elderly populace, and rising occurrence of chronic health conditions.

The industry players have been constantly spending in emerging innovative items for chronic pain treatment. Wearable tech for the treatment of long-lasting pain is one of the major improvements in the chronic pain treatment industry.

The World Health Organization projects a substantial surge in the worldwide populace aged 60 and more from 12% to 22% between 2015 and 2050. This demographic move has augmented the occurrence of chronic pain, mainly among elder patients in nursing homes, posing a challenge for care facilities.

To confront this problem, a combination of pharmacological, non-pharmacological (physical and occupational therapies), and occupational therapies is employed, positively impacting the chronic pain treatment market.

Chronic illnesses such as sickle-cell anemia, osteoarthritis, fibromyalgia, cancer, and autoimmune illnesses such as rheumatoid arthritis are dominant worldwide, requiring therapeutic interventions for better pain management. The extensive use of treatments such as physiotherapy, medication, and psychological therapy reflects the rising load of chronic diseases and their impact on healthcare systems globally.

Key Insights

The drugs category is projected to advance at a CAGR of around 7.7% and lead the industry share because of increasing chronic pain cases such as severe headaches, lower back pain, and facial pain.

Reasons contributing to this development include the growing worldwide elderly populace, sedentary lifestyles, and an increase in surgical procedures.

The need for painkillers is projected to intensify in response to these trends over the forecast period.

In 2023, the musculoskeletal category had a 40% industry share because of the high occurrence of musculoskeletal illnesses such as fibromyalgia, osteoarthritis, and rheumatoid arthritis.

In 2019-2021, as many as 53.2 million U.S. adults had these conditions: different kinds of arthritis (including rheumatoid arthritis), gout, lupus or fibromyalgia, according to NHIS (National Health Interview Survey).

Musculoskeletal segment is predicted to have a CAGR of 7.3% until the end of the forecast period due to some factors e.g. increase arthritis prevalence and back pain which is responsible for disability all over the world being at the top.

During the projection period, the cancer pain category is projected to advance at a CAGR of 8.0% based on indication.

The National Cancer Institute classifies cancer as a principal worldwide reason of death, with forecasts indicating increasing new cases and demises by 2040.

Growing cancer survivor numbers contribute to industry development because of the long-lasting and commonly severe pain related with the disease.

The APAC region is set to be the fastest-growing industry with a CAGR of 7.8% during the projection period, propelled by advancing healthcare infrastructure, increasing disposable income, rising elderly populace, and growing chronic pain prevalence.

Asia's elderly populace is projected to double from 395 million in 2019 to 587 million by 2030, paying to advanced demand for pain treatment medications and devices.

In 2023, the North American region, holding a 55% industry share, advantages from developed healthcare infrastructure, high healthcare spending, and extensive obtainability of advanced pain treatment solutions.

Table of Contents

Chapter 1. Research Scope

• 1.1. Research Objectives
• 1.2. Market Definition
• 1.3. Analysis Period
• 1.4. Market Size Breakdown by Segments
  • 1.4.1. Market size breakdown, by product
  • 1.4.2. Market size breakdown, by indication
  • 1.4.3. Market size breakdown, by application
  • 1.4.4. Market size breakdown, by distribution channel
  • 1.4.5. Market size breakdown, by end user
  • 1.4.6. Market size breakdown, by region
  • 1.4.7. Market size breakdown, by country
• 1.5. Market Data Reporting Unit
  • 1.5.1. Value
• 1.6. Key Stakeholders

Chapter 2. Research Methodology

• 2.1. Secondary Research
  • 2.1.1. Paid
  • 2.1.2. Unpaid
  • 2.1.3. P&S Intelligence database
• 2.2. Primary Research
• 2.3. Market Size Estimation
• 2.4. Data Triangulation
• 2.5. Currency Conversion Rates
• 2.6. Assumptions for the Study
• 2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

• 5.1. Market Dynamics
  • 5.1.1. Trends
  • 5.1.2. Drivers
  • 5.1.3. Restraints/challenges
  • 5.1.4. Impact analysis of drivers/restraints
• 5.2. Impact of COVID-19
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Bargaining power of buyers
  • 5.3.2. Bargaining power of suppliers
  • 5.3.3. Threat of new entrants
  • 5.3.4. Intensity of rivalry
  • 5.3.5. Threat of substitutes

Chapter 6. Global Market

• 6.1. Overview
• 6.2. Market Revenue, by Product (2017-2030)
• 6.3. Market Revenue, by Indication (2017-2030)
• 6.4. Market Revenue, by Application (2017-2030)
• 6.5. Market Revenue, by Distribution Channel (2017-2030)
• 6.6. Market Revenue, by End User (2017-2030)
• 6.7. Market Revenue, by Region (2017-2030)

Chapter 7. North America Market

• 7.1. Overview
• 7.2. Market Revenue, by Product (2017-2030)
• 7.3. Market Revenue, by Indication (2017-2030)
• 7.4. Market Revenue, by Application (2017-2030)
• 7.5. Market Revenue, by Distribution Channel (2017-2030)
• 7.6. Market Revenue, by End User (2017-2030)
• 7.7. Market Revenue, by Country (2017-2030)

Chapter 8. Europe Market

• 8.1. Overview
• 8.2. Market Revenue, by Product (2017-2030)
• 8.3. Market Revenue, by Indication (2017-2030)
• 8.4. Market Revenue, by Application (2017-2030)
• 8.5. Market Revenue, by Distribution Channel (2017-2030)
• 8.6. Market Revenue, by End User (2017-2030)
• 8.7. Market Revenue, by Country (2017-2030)

Chapter 9. APAC Market

• 9.1. Overview
• 9.2. Market Revenue, by Product (2017-2030)
• 9.3. Market Revenue, by Indication (2017-2030)
• 9.4. Market Revenue, by Application (2017-2030)
• 9.5. Market Revenue, by Distribution Channel (2017-2030)
• 9.6. Market Revenue, by End User (2017-2030)
• 9.7. Market Revenue, by Country (2017-2030)

Chapter 10. LATAM Market

• 10.1. Overview
• 10.2. Market Revenue, by Product (2017-2030)
• 10.3. Market Revenue, by Indication (2017-2030)
• 10.4. Market Revenue, by Application (2017-2030)
• 10.5. Market Revenue, by Distribution Channel (2017-2030)
• 10.6. Market Revenue, by End User (2017-2030)
• 10.7. Market Revenue, by Country (2017-2030)

Chapter 11. MEA Market

• 11.1. Overview
• 11.2. Market Revenue, by Product (2017-2030)
• 11.3. Market Revenue, by Indication (2017-2030)
• 11.4. Market Revenue, by Application (2017-2030)
• 11.5. Market Revenue, by Distribution Channel (2017-2030)
• 11.6. Market Revenue, by End User (2017-2030)
• 11.7. Market Revenue, by Country (2017-2030)

Chapter 12. U.S. Market

• 12.1. Overview
• 12.2. Market Revenue, by Product (2017-2030)
• 12.3. Market Revenue, by Indication (2017-2030)
• 12.4. Market Revenue, by Application (2017-2030)
• 12.5. Market Revenue, by Distribution Channel (2017-2030)
• 12.6. Market Revenue, by End User (2017-2030)

Chapter 13. Canada Market

• 13.1. Overview
• 13.2. Market Revenue, by Product (2017-2030)
• 13.3. Market Revenue, by Indication (2017-2030)
• 13.4. Market Revenue, by Application (2017-2030)
• 13.5. Market Revenue, by Distribution Channel (2017-2030)
• 13.6. Market Revenue, by End User (2017-2030)

Chapter 14. Germany Market

• 14.1. Overview
• 14.2. Market Revenue, by Product (2017-2030)
• 14.3. Market Revenue, by Indication (2017-2030)
• 14.4. Market Revenue, by Application (2017-2030)
• 14.5. Market Revenue, by Distribution Channel (2017-2030)
• 14.6. Market Revenue, by End User (2017-2030)

Chapter 15. France Market

• 15.1. Overview
• 15.2. Market Revenue, by Product (2017-2030)
• 15.3. Market Revenue, by Indication (2017-2030)
• 15.4. Market Revenue, by Application (2017-2030)
• 15.5. Market Revenue, by Distribution Channel (2017-2030)
• 15.6. Market Revenue, by End User (2017-2030)

Chapter 16. U.K. Market

• 16.1. Overview
• 16.2. Market Revenue, by Product (2017-2030)
• 16.3. Market Revenue, by Indication (2017-2030)
• 16.4. Market Revenue, by Application (2017-2030)
• 16.5. Market Revenue, by Distribution Channel (2017-2030)
• 16.6. Market Revenue, by End User (2017-2030)

Chapter 17. Italy Market

• 17.1. Overview
• 17.2. Market Revenue, by Product (2017-2030)
• 17.3. Market Revenue, by Indication (2017-2030)
• 17.4. Market Revenue, by Application (2017-2030)
• 17.5. Market Revenue, by Distribution Channel (2017-2030)
• 17.6. Market Revenue, by End User (2017-2030)

Chapter 18. Spain Market

• 18.1. Overview
• 18.2. Market Revenue, by Product (2017-2030)
• 18.3. Market Revenue, by Indication (2017-2030)
• 18.4. Market Revenue, by Application (2017-2030)
• 18.5. Market Revenue, by Distribution Channel (2017-2030)
• 18.6. Market Revenue, by End User (2017-2030)

Chapter 19. Japan Market

• 19.1. Overview
• 19.2. Market Revenue, by Product (2017-2030)
• 19.3. Market Revenue, by Indication (2017-2030)
• 19.4. Market Revenue, by Application (2017-2030)
• 19.5. Market Revenue, by Distribution Channel (2017-2030)
• 19.6. Market Revenue, by End User (2017-2030)

Chapter 20. China Market

• 20.1. Overview
• 20.2. Market Revenue, by Product (2017-2030)
• 20.3. Market Revenue, by Indication (2017-2030)
• 20.4. Market Revenue, by Application (2017-2030)
• 20.5. Market Revenue, by Distribution Channel (2017-2030)
• 20.6. Market Revenue, by End User (2017-2030)

Chapter 21. India Market

• 21.1. Overview
• 21.2. Market Revenue, by Product (2017-2030)
• 21.3. Market Revenue, by Indication (2017-2030)
• 21.4. Market Revenue, by Application (2017-2030)
• 21.5. Market Revenue, by Distribution Channel (2017-2030)
• 21.6. Market Revenue, by End User (2017-2030)

Chapter 22. Australia Market

• 22.1. Overview
• 22.2. Market Revenue, by Product (2017-2030)
• 22.3. Market Revenue, by Indication (2017-2030)
• 22.4. Market Revenue, by Application (2017-2030)
• 22.5. Market Revenue, by Distribution Channel (2017-2030)
• 22.6. Market Revenue, by End User (2017-2030)

Chapter 23. South Korea Market

• 23.1. Overview
• 23.2. Market Revenue, by Product (2017-2030)
• 23.3. Market Revenue, by Indication (2017-2030)
• 23.4. Market Revenue, by Application (2017-2030)
• 23.5. Market Revenue, by Distribution Channel (2017-2030)
• 23.6. Market Revenue, by End User (2017-2030)

Chapter 24. Brazil Market

• 24.1. Overview
• 24.2. Market Revenue, by Product (2017-2030)
• 24.3. Market Revenue, by Indication (2017-2030)
• 24.4. Market Revenue, by Application (2017-2030)
• 24.5. Market Revenue, by Distribution Channel (2017-2030)
• 24.6. Market Revenue, by End User (2017-2030)

Chapter 25. Mexico Market

• 25.1. Overview
• 25.2. Market Revenue, by Product (2017-2030)
• 25.3. Market Revenue, by Indication (2017-2030)
• 25.4. Market Revenue, by Application (2017-2030)
• 25.5. Market Revenue, by Distribution Channel (2017-2030)
• 25.6. Market Revenue, by End User (2017-2030)

Chapter 26. Saudi Arabia Market

• 26.1. Overview
• 26.2. Market Revenue, by Product (2017-2030)
• 26.3. Market Revenue, by Indication (2017-2030)
• 26.4. Market Revenue, by Application (2017-2030)
• 26.5. Market Revenue, by Distribution Channel (2017-2030)
• 26.6. Market Revenue, by End User (2017-2030)

Chapter 27. South Africa Market

• 27.1. Overview
• 27.2. Market Revenue, by Product (2017-2030)
• 27.3. Market Revenue, by Indication (2017-2030)
• 27.4. Market Revenue, by Application (2017-2030)
• 27.5. Market Revenue, by Distribution Channel (2017-2030)
• 27.6. Market Revenue, by End User (2017-2030)

Chapter 28. U.A.E. Market

• 28.1. Overview
• 28.2. Market Revenue, by Product (2017-2030)
• 28.3. Market Revenue, by Indication (2017-2030)
• 28.4. Market Revenue, by Application (2017-2030)
• 28.5. Market Revenue, by Distribution Channel (2017-2030)
• 28.6. Market Revenue, by End User (2017-2030)

Chapter 29. Competitive Landscape

• 29.1. List of Market Players and their Offerings
• 29.2. Competitive Benchmarking of Key Players
• 29.3. Product Benchmarking of Key Players
• 29.4. Recent Strategic Developments

Chapter 30. Company Profiles

• 30.1. Eli Lilly and Company
  • 30.1.1. Business overview
  • 30.1.2. Product and service offerings
  • 30.1.3. Key financial summary
• 30.2. GlaxoSmithKline plc
  • 30.2.1. Business overview
  • 30.2.2. Product and service offerings
  • 30.2.3. Key financial summary
• 30.3. Pfizer Inc.
  • 30.3.1. Business overview
  • 30.3.2. Product and service offerings
  • 30.3.3. Key financial summary
• 30.4. Medtronic plc
  • 30.4.1. Business overview
  • 30.4.2. Product and service offerings
  • 30.4.3. Key financial summary
• 30.5. Abbott Laboratories
  • 30.5.1. Business overview
  • 30.5.2. Product and service offerings
  • 30.5.3. Key financial summary
• 30.6. Boston Scientific Corporation
  • 30.6.1. Business overview
  • 30.6.2. Product and service offerings
  • 30.6.3. Key financial summary
• 30.7. Novartis AG
  • 30.7.1. Business overview
  • 30.7.2. Product and service offerings
  • 30.7.3. Key financial summary
• 30.8. Johnson & Johnson Services Inc.
  • 30.8.1. Business overview
  • 30.8.2. Product and service offerings
  • 30.8.3. Key financial summary
• 30.9. AstraZeneca PLC
  • 30.9.1. Business overview
  • 30.9.2. Product and service offerings
  • 30.9.3. Key financial summary
• 30.10. Bristol-Myers Squibb Company
  • 30.10.1. Business overview
  • 30.10.2. Product and service offerings
  • 30.10.3. Key financial summary
• 30.11. Becton, Dickinson and Company
  • 30.11.1. Business overview
  • 30.11.2. Product and service offerings
  • 30.11.3. Key financial summary
• 30.12. Sanofi S.A.
  • 30.12.1. Business overview
  • 30.12.2. Product and service offerings
  • 30.12.3. Key financial summary
• 30.13. Teva Pharmaceutical Industries Limited
  • 30.13.1. Business overview
  • 30.13.2. Product and service offerings
  • 30.13.3. Key financial summary
• 30.14. AbbVie Inc.
  • 30.14.1. Business overview
  • 30.14.2. Product and service offerings
  • 30.14.3. Key financial summary
• 30.15. Paradigm Biopharmaceuticals Limited
  • 30.15.1. Business overview
  • 30.15.2. Product and service offerings
  • 30.15.3. Key financial summary

Chapter 31. Appendix

• 31.1. Abbreviations
• 31.2. Sources and References
• 31.3. Related Reports